Quasispecies and its impact on viral hepatitis

Esteban Domingo, Jordi Gomez, Esteban Domingo, Jordi Gomez

Abstract

Quasispecies dynamics mediates adaptability of RNA viruses through a number of mechanisms reviewed in the present article, with emphasis on the medical implications for the hepatitis viruses. We discuss replicative and non-replicative molecular mechanisms of genome variation, modulating effects of mutant spectra, and several modes of viral evolution that can affect viral pathogenesis. Relevant evolutionary events include the generation of minority virus variants with altered functional properties, and alterations of mutant spectrum complexity that can affect disease progression or response to treatment. The widespread occurrence of resistance to antiviral drugs encourages new strategies to control hepatic viral disease such as combination therapies and lethal mutagenesis. In particular, ribavirin may be exerting in some cases its antiviral activity with participation of its mutagenic action. Despite many unanswered questions, here we document that quasispecies dynamics has provided an interpretation of the adaptability of the hepatitis viruses, with features conceptually similar to those observed with other RNA viruses, a reflection of the common underlying Darwinian principles.

Figures

Fig. 1
Fig. 1
Schematic representation of viral quasispecies and fitness variations. (A) An infected individual contains multiple, replicating viral quasispecies, even within the same organ. Here two mutant spectra are depicted with their consensus sequences. Each horizontal line represents a genome, and each symbol on a line represents a type of mutation. Real viral quasispecies can contain thousands of continuously mutating genomes that conform huge mutant clouds. (B) The passage regime of the virus can affect virus population fitness. Small arrows represent repeated bottleneck passages which result in fitness decrease. The large arrow represents large population passages that generally result in fitness gain. Fluctuations in fitness shown at high and low fitness values (at the two small angles of the fitness triangle) have been observed experimentally and interpreted as the stochastic effect of mutations on fitness when fitness gain is limited by population size or when fitness is very low. [Based in (Escarmís et al., 2006, Novella, 2003, Novella et al., 1999); figure modified from (Domingo et al., 2006), with permission].
Fig. 2
Fig. 2
Diversity of viral sequences and shift in the HCV quasispecies in serum and liver over time, in a non-progressive patient chronically infected with HCV. Amino acid sequences at the coding junction region E2-p7-NS2 quasispecies in serum (S0 to S5) and liver (L0 and L5), were grouped in clusters represented by histograms. Groups were made according to similarity, so that any amino acid sequence in any subgroup shared one or more amino acid replacements which were not present together in the same amino acid sequence subset in the same or in other samples. That is, inter-group amino acid sequences consisted in one or two substitutions, and intra-group amino acid sequences differed in single point substitutions. The same colors and patterns identify identical subgroups. Mutations in the consensus sequences of the viral quasispecies over time are shown at the bottom of each histogram (each symbol represents one mutation). Shannon entropy and genetic distance are shown below the respective histogram. Based in (Cabot et al., 2001).

References

    1. Abe K., Inchauspe G., Fujisawa K. Genomic characterization and mutation rate of hepatitis C virus isolated from a patient who contracted hepatitis during an epidemic of non-A, non-B hepatitis in Japan. J. Gen. Virol. 1992;73:2725–2729.
    1. Agol V.I. Molecular mechanisms of poliovirus variation and evolution. Curr. Top. Microbiol. Immunol. 2006;299:211–259.
    1. Airaksinen A., Pariente N., Menendez-Arias L., Domingo E. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology. 2003;311(2):339–349.
    1. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., Brown N., Condreay L.D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998;27(6):1670–1677.
    1. Anderson J.P., Daifuku R., Loeb L.A. Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol. 2004;58:183–205.
    1. Arnold J.J., Ghosh S.K., Cameron C.E. Poliovirus RNA-dependent RNA polymerase (3D(pol)). Divalent cation modulation of primer, template, and nucleotide selection. J. Biol. Chem. 1999;274(52):37060–37069.
    1. Arnold J.J., Vignuzzi M., Stone J.K., Andino R., Cameron C.E. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J. Biol. Chem. 2005;280(27):25706–25716.
    1. Asahina Y., Izumi N., Enomoto N., Uchihara M., Kurosaki M., Onuki Y., Nishimura Y., Ueda K., Tsuchiya K., Nakanishi H., Kitamura T., Miyake S. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J. Hepatol. 2005;43(4):623–629.
    1. Bartholomeusz A., Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J. Med. Virol. 2006;78(Suppl 1):S52–S55.
    1. Bartholomeusz A., Locarnini S.A. Antiviral drug resistance: clinical consequences and molecular aspects. Semin. Liver Dis. 2006;26(2):162–170.
    1. Batschelet E., Domingo E., Weissmann C. The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate. Gene. 1976;1(1):27–32.
    1. Biebricher C.K., Eigen M. The error threshold. Virus Res. 2005;107(2):117–127.
    1. Biebricher C.K., Eigen M. What is a quasispecies? Curr. Top. Microbiol. Immunol. 2006;299:1–31.
    1. Boerlijst M.C., Boenhoefer S., Nowak M.A. Viral quasispecies and recombination. Proc. R. Soc. Lond. B. 1996;263:1577–1584.
    1. Bollyky P.L., Rambaut A., Harvey P.H., Holmes E.C. Recombination between sequences of hepatitis B virus from different genotypes. J. Mol. Evol. 1996;42(2):97–102.
    1. Bonhoeffer S., May R.M., Shaw G.M., Nowak M.A. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. U.S.A. 1997;94(13):6971–6976.
    1. Bonvin M., Achermann F., Greeve I., Stroka D., Keogh A., Inderbitzin D., Candinas D., Sommer P., Wain-Hobson S., Vartanian J.P., Greeve J. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology. 2006;43(6):1364–1374.
    1. Borrow P., Lewicki H., Wei X., Horwitz M.S., Peffer N., Meyers H., Nelson J.A., Gairin J.E., Hahn B.H., Oldstone M.B., Shaw G.M. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 1997;3(2):205–211.
    1. Bowen D.G., Walker C.M. The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? J. Hepatol. 2005;42(3):408–417.
    1. Bowen D.G., McCaughan G.W., Bertolino P. Intrahepatic immunity: a tale of two sites? Trends Immunol. 2005;26(10):512–517.
    1. Briones C., Domingo E., Molina-París C. Memory in retroviral quasispecies: experimental evidence and theoretical model for human immunodeficiency virus. J. Mol. Biol. 2003;331(1):213–229.
    1. Cabot B., Martell M., Esteban J.I., Sauleda S., Otero T., Esteban R., Guardia J., Gomez J. Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver. J. Virol. 2000;74(2):805–811.
    1. Cabot B., Martell M., Esteban J.I., Piron M., Otero T., Esteban R., Guardia J., Gómez J. Longitudinal evaluation of the structure of replicating and circulating hepatitis C virus quasispecies in nonprogressive chronic hepatitis C patients. J. Virol. 2001;75(24):12005–12013.
    1. Chambers T.J., Fan X., Droll D.A., Hembrador E., Slater T., Nickells M.W., Dustin L.B., Dibisceglie A.M. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J. Virol. 2005;79(5):3071–3083.
    1. Chang K.M., Rehermann B., McHutchison J.G., Pasquinelli C., Southwood S., Sette A., Chisari F.V. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest. 1997;100(9):2376–2385.
    1. Cheng C.P., Serviene E., Nagy P.D. Suppression of viral RNA recombination by a host exoribonuclease. J. Virol. 2006;80(6):2631–2640.
    1. Chetverin A.B., Kopein D.S., Chetverina H.V., Demidenko A.A., Ugarov V.I. Viral RNA-directed RNA polymerases use diverse mechanisms to promote recombination between RNA molecules. J. Biol. Chem. 2005;280(10):8748–8755.
    1. Chiu Y.L., Greene W.C. Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol. 2006;27(6):291–297.
    1. Chohan B., Lavreys L., Rainwater S.M., Overbaugh J. Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J. Virol. 2005;79(16):10701–10708.
    1. Cicin-Sain L., Podlech J., Messerle M., Reddehase M.J., Koszinowski U.H. Frequent coinfection of cells explains functional in vivo complementation between cytomegalovirus variants in the multiply infected host. J. Virol. 2005;79(15):9492–9502.
    1. Ciurea A., Hunziker L., Martinic M.M., Oxenius A., Hengartner H., Zinkernagel R.M. CD4+ T-cell-epitope escape mutant virus selected in vivo. Nat. Med. 2001;7(7):795–800.
    1. Clementi M. Intra-host genetic heterogeneity of hepatitis C virus and biomedical implications. J. Biol. Regul. Homeost. Agents. 2003;17(2):120–124.
    1. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267(5197):483–489.
    1. Contreras A.M., Hiasa Y., He W., Terella A., Schmidt E.V., Chung R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 2002;76(17):8505–8517.
    1. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., Houghton M., Parham P., Walker C.M. Analysis of a successful immune response against hepatitis C virus. Immunity. 1999;10(4):439–449.
    1. Costa-Mattioli M., Ferre V., Casane D., Perez-Bercoff R., Coste-Burel M., Imbert-Marcille B.M., Andre E.C., Bressollette-Bodin C., Billaudel S., Cristina J. Evidence of recombination in natural populations of hepatitis A virus. Virology. 2003;311(1):51–59.
    1. Cristina J., Colina R. Evidence of structural genomic region recombination in Hepatitis C virus. Virol. J. 2006;3:53.
    1. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y.N., Hong Z., Andino R., Cameron C.E. The broad-spectrum antiviral ribonucleotide, ribavirin, is an RNA virus mutagen. Nat. Med. 2000;6:1375–1379.
    1. Crotty S., Cameron C.E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U.S.A. 2001;98(12):6895–6900.
    1. Dawson T.R., Sansam C.L., Emeson R.B. Structure and sequence determinants required for the RNA editing of ADAR2 substrates. J. Biol. Chem. 2004;279(6):4941–4951.
    1. de la Torre J.C., Holland J.J. RNA virus quasispecies populations can suppress vastly superior mutant progeny. J. Virol. 1990;64(12):6278–6281.
    1. Deforges S., Evlashev A., Perret M., Sodoyer M., Pouzol S., Scoazec J.Y., Bonnaud B., Diaz O., Paranhos-Baccala G., Lotteau V., Andre P. Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo. J. Gen. Virol. 2004;85(Pt 9):2515–2523.
    1. Delaney W.E.T., Yang H., Westland C.E., Das K., Arnold E., Gibbs C.S., Miller M.D., Xiong S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 2003;77(21):11833–11841.
    1. Domingo E. RNA virus evolution and the control of viral disease. Prog. Drug Res. 1989;33:93–133.
    1. Domingo E. Quasispecies and the development of new antiviral strategies. Prog. Drug Res. 2003;60:133–158.
    1. Domingo, E., (Ed.), 2005. Virus entry into error catastrophe as a new antiviral strategy. Virus Res. 107, 115–228.
    1. Domingo, E., (Ed.), 2006. Quasispecies: concepts and implications for virology. Curr. Top. Microbiol. Immunol. 299.
    1. Domingo, E., 2007. Virus Evolution, in: Knipe, D.M., Howley, P.M., (Eds.), Fields Virology, in press.
    1. Domingo E., Holland J.J. Complications of RNA heterogeneity for the engineering of virus vaccines and antiviral agents. Genet. Eng. (N.Y.) 1992;14:13–31.
    1. Domingo E., Biebricher C., Eigen M., Holland J.J. Landes Bioscience; Austin: 2001. Quasispecies and RNA Virus Evolution: Principles and Consequences.
    1. Domingo E., Martin V., Perales C., Grande-Perez A., Garcia-Arriaza J., Arias A. Viruses as quasispecies: biological implications. Curr. Top. Microbiol. Immunol. 2006;299:51–82.
    1. Drake J.W., Holland J.J. Mutation rates among RNA viruses. Proc. Natl. Acad. Sci. U.S.A. 1999;96:13910–13913.
    1. Earl D.J., Deem M.W. Evolvability is a selectable trait. Proc. Natl. Acad. Sci. U.S.A. 2004;101(32):11531–11536.
    1. Eigen M. New concepts for dealing with the evolution of nucleic acids. Cold Spring Harb. Symp. Quant. Biol. 1987;52:307–320.
    1. Eigen M. Natural selection: a phase transition? Biophys. Chem. 2000;85:101–123.
    1. Eigen M. Error catastrophe and antiviral strategy. Proc. Natl. Acad. Sci. U.S.A. 2002;99(21):13374–13376.
    1. Eigen M., Biebricher C.K. Sequence space and quasispecies distribution. In: Domingo E., Ahlquist P., Holland J.J., editors. Vol. 3. CRC Press; Boca Raton, FL: 1988. (RNA Genetics).
    1. Eigen M., Schuster P. Springer; Berlin: 1979. The hypercycle. A principle of natural self-organization.
    1. Enomoto N., Kurosaki M., Tanaka Y., Marumo F., Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J. Gen. Virol. 1994;75(Pt 6):1361–1369.
    1. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Izumi N., Marumo F., Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 1995;96(1):224–230.
    1. Eren R., Landstein D., Terkieltaub D., Nussbaum O., Zauberman A., Ben-Porath J., Gopher J., Buchnick R., Kovjazin R., Rosenthal-Galili Z., Aviel S., Ilan E., Shoshany Y., Neville L., Waisman T., Ben-Moshe O., Kischitsky A., Foung S.K., Keck Z.Y., Pappo O., Eid A., Jurim O., Zamir G., Galun E., Dagan S. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J. Virol. 2006;80(6):2654–2664.
    1. Erickson A.L., Kimura Y., Igarashi S., Eichelberger J., Houghton M., Sidney J., McKinney D., Sette A., Hughes A.L., Walker C.M. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity. 2001;15(6):883–895.
    1. Escarmís C., Lázaro E., Manrubia S.C. Population bottlenecks in quasispecies dynamics. Curr. Top. Microbiol. Immunol. 2006;299:141–170.
    1. Esteban J.I., Gómez J., Martell M., Guardia J. Hepatitis C Virus. In: Wilson R.A., editor. Viral Hepatitis. Marcel Dekker; New York: 1997.
    1. Esteban J.I., Martell M., Carman W.F., Gomez J. The impact of rapid evolution of the hepatitis viruses. In: Domingo E., Webster R.G., Holland J.J., editors. Origin and Evolution of Viruses. Academic Press; San Diego: 1999.
    1. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., Strazzera A., Chien D.Y., Munoz S.J., Balestrieri A., Purcell R.H., Alter H.J. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000;288(5464):339–344.
    1. Farci P., Strazzera R., Alter H.J., Farci S., Degioannis D., Coiana A., Peddis G., Usai F., Serra G., Chessa L., Diaz G., Balestrieri A., Purcell R.H. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl. Acad. Sci. U.S.A. 2002;99(5):3081–3086.
    1. Farci P., Quinti I., Farci S., Alter H.J., Strazzera R., Palomba E., Coiana A., Cao D., Casadei A.M., Ledda R., Iorio R., Vegnente A., Diaz G., Tovo P.A. Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc. Natl. Acad. Sci. U.S.A. 2006;103(22):8475–8480.
    1. Ferrer-Orta C., Arias A., Escarmis C., Verdaguer N. A comparison of viral RNA-dependent RNA polymerases. Curr. Opin. Struct. Biol. 2006;16(1):27–34.
    1. Figlerowicz M., Alejska M., Kurzynska-Kokorniak A., Figlerowicz M. Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections. Med. Res. Rev. 2003;23(4):488–518.
    1. Forton D.M., Karayiannis P., Mahmud N., Taylor-Robinson S.D., Thomas H.C. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J. Virol. 2004;78(10):5170–5183.
    1. Franco S., Gimenez-Barcons M., Puig-Basagoiti F., Furcic I., Sanchez-Tapias J.M., Rodes J., Saiz J.C. Characterization and evolution of NS5A quasispecies of hepatitis C virus genotype 1b in patients with different stages of liver disease. J. Med. Virol. 2003;71(2):195–204.
    1. Friedberg E.C., Walker G.C., Siede W., Wood R.D., Schultz R.A., Ellenberger T. American Society for Microbiology; Washington, DC: 2006. DNA Repair and Mutagenesis.
    1. Friedrich T.C., Dodds E.J., Yant L.J., Vojnov L., Rudersdorf R., Cullen C., Evans D.T., Desrosiers R.C., Mothe B.R., Sidney J., Sette A., Kunstman K., Wolinsky S., Piatak M., Lifson J., Hughes A.L., Wilson N., O’Connor D.H., Watkins D.I. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat. Med. 2004;10(3):275–281.
    1. Fu L., Cheng Y.C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem. Pharmacol. 1998;55(10):1567–1572.
    1. Gallei A., Pankraz A., Thiel H.J., Becher P. RNA recombination in vivo in the absence of viral replication. J. Virol. 2004;78(12):6271–6281.
    1. Gaudy C., Lambele M., Moreau A., Veillon P., Lunel F., Goudeau A. Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome. J. Clin. Microbiol. 2005;43(2):750–754.
    1. Gauss-Muller V., Kusov Y.Y. Replication of a hepatitis A virus replicon detected by genetic recombination in vivo. J. Gen. Virol. 2002;83(Pt 9):2183–2192.
    1. Giménez-Barcons M., Ibañez A., Tajahuerce A., Sánchez-Tapias J.M., Rodes J., Martinez M.A., Saiz J.C. Genetic evolution of hepatitis G virus in chronically infected individual patients. J. Gen. Virol. 1998;79:2623–2629.
    1. Gmyl A.P., Korshenko S.A., Belousov E.V., Khitrina E.V., Agol V.I. Nonreplicative homologous RNA recombination: promiscuous joining of RNA pieces? RNA. 2003;9(10):1221–1231.
    1. Gomez, J., Cacho, I., 2001. Can Nietzsche power relationships be experimentally approached with theoretical and viral quasispecies? Contributions to Science (Revista del Institut d’Estudis Catalans): 2 (1), 103–108.
    1. Gomez J., Martell M., Quer J., Cabot B., Esteban J.I. Hepatitis C viral quasispecies. J. Viral Hepat. 1999;6(1):3–16.
    1. González-López C., Arias A., Pariente N., Gómez-Mariano G., Domingo E. Preextinction viral RNA can interfere with infectivity. J. Virol. 2004;78(7):3319–3324.
    1. Gonzalez-Peralta R.P., Qian K., She J.Y., Davis G.L., Ohno T., Mizokami M., Lau J.Y. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J. Med. Virol. 1996;49(3):242–247.
    1. Goulder P., Price D., Nowak M., Rowland-Jones S., Phillips R., McMichael A. Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses. Immunol. Rev. 1997;159:17–29.
    1. Graci J.D., Cameron C.E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 2006;16(1):37–48.
    1. Grande-Pérez A., Lazaro E., Lowenstein P., Domingo E., Manrubia S.C. Suppression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. U.S.A. 2005;102(12):4448–4452.
    1. Gratton S., Cheynier R., Dumaurier M.J., Oksenhendler E., Wain-Hobson S. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc. Natl. Acad. Sci. U.S.A. 2000;97(26):14566–14571.
    1. Harris K.S., Brabant W., Styrchak S., Gall A., Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 2005;67(1):1–9.
    1. Hartwig D., Schutte C., Warnecke J., Dorn I., Hennig H., Kirchner H., Schlenke P. The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells. J. Viral. Hepat. 2006;13(3):150–157.
    1. Hayashi J., Kishihara Y., Yamaji K., Furusyo N., Yamamoto T., Pae Y., Etoh Y., Ikematsu H., Kashiwagi S. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology. 1997;25(3):697–701.
    1. Hohne M., Schreier E., Roggendorf M. Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak. Arch. Virol. 1994;137(1–2):25–34.
    1. Holland J. Transitions in understanding of RNA viruses: an historical perspective. Curr. Top. Microbiol. Immunol. 2006;299:371–401.
    1. Holland J.J., Spindler K., Horodyski F., Grabau E., Nichol S., VandePol S. Rapid evolution of RNA genomes. Science. 1982;215(4540):1577–1585.
    1. Holland J.J., de la Torre J.C., Steinhauer D.A., Clarke D., Duarte E., Domingo E. Virus mutation frequencies can be greatly underestimated by monoclonal antibody neutralization of virions. J. Virol. 1989;63(12):5030–5036.
    1. Holland J.J., de La Torre J.C., Steinhauer D.A. RNA virus populations as quasispecies. Curr. Top. Microbiol. Immunol. 1992;176:1–20.
    1. Honda M., Kaneko S., Sakai A., Unoura M., Murakami S., Kobayashi K. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology. 1994;20(5):1144–1151.
    1. Hong Z. The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact? Hepatology. 2003;38(4):807–810.
    1. Hsu H.Y., Chang M.H., Liaw S.H., Ni Y.H., Chen H.L. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology. 1999;30(5):1312–1317.
    1. Imazeki F., Omata M., Ohto M. Heterogeneity and evolution rates of delta virus RNA sequences. J. Virol. 1990;64(11):5594–5599.
    1. Isnard M., Granier M., Frutos R., Reynaud B., Peterschmitt M. Quasispecies nature of three maize streak virus isolates obtained through different modes of selection from a population used to assess response to infection of maize cultivars. J. Gen. Virol. 1998;79:3091–3099.
    1. Jang S.J., Wang L.F., Radkowski M., Rakela J., Laskus T. Differences between hepatitis C virus 5′ untranslated region quasispecies in serum and liver. J. Gen. Virol. 1999;80(Pt 3):711–716.
    1. Kalinina O., Norder H., Mukomolov S., Magnius L.O. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J. Virol. 2002;76(8):4034–4043.
    1. Kamp C. A quasispecies approach to viral evolution in the context of an adaptive immune system. Microbes Infect. 2003;5(15):1397–1405.
    1. Kanazawa Y., Hayashi N., Mita E., Li T., Hagiwara H., Kasahara A., Fusamoto H., Kamada T. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology. 1994;20(5):1121–1130.
    1. Kanda T., Yokosuka O., Imazeki F., Tanaka M., Shino Y., Shimada H., Tomonaga T., Nomura F., Nagao K., Ochiai T., Saisho H. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J. Viral. Hepat. 2004;11(6):479–487.
    1. Kawada M., Igarashi H., Takeda A., Tsukamoto T., Yamamoto H., Dohki S., Takiguchi M., Matano T. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques. J. Virol. 2006;80(4):1949–1958.
    1. Keulen W., van Wijk A., Schuurman R., Berkhout B., Boucher C.A. Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential. AIDS. 1999;13(11):1343–1349.
    1. Kimata J.T., Kuller L., Anderson D.B., Dailey P., Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 1999;5(5):535–541.
    1. Koenig S., Conley A.J., Brewah Y.A., Jones G.M., Leath S., Boots L.J., Davey V., Pantaleo G., Demarest J.F., Carter C. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1995;1(4):330–336.
    1. Koizumi K., Enomoto N., Kurosaki M., Murakami T., Izumi N., Marumo F., Sato C. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology. 1995;22(1):30–35.
    1. Kojima M., Osuga T., Tsuda F., Tanaka T., Okamoto H. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees. Virology. 1994;204(2):665–672.
    1. Kurosaki M., Enomoto N., Nouchi T., Sakuma I., Marumo F., Sato C. Fraction-specific populations of the hypervariable region of the hepatitis C virus in a patient with cryoglobulinemia. J. Med. Virol. 1995;46(4):403–408.
    1. Lada O., Benhamou Y., Poynard T., Thibault V. Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of “a” determinant variants. J. Virol. 2006;80(6):2968–2975.
    1. Lanford R.E., Chavez D., Guerra B., Lau J.Y., Hong Z., Brasky K.M., Beames B. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 2001;75(17):8074–8081.
    1. Laskus T., Wilkinson J., Gallegos-Orozco J.F., Radkowski M., Adair D.M., Nowicki M., Operskalski E., Buskell Z., Seeff L.B., Vargas H., Rakela J. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology. 2004;127(3):764–776.
    1. Le Guen B., Squadrito G., Nalpas B., Berthelot P., Pol S., Brechot C. Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Hepatology. 1997;25(5):1250–1254.
    1. Lee C.M., Bih F.Y., Chao Y.C., Govindarajan S., Lai M.M. Evolution of hepatitis delta virus RNA during chronic infection. Virology. 1992;188(1):265–273.
    1. Leslie A.J., Pfafferott K.J., Chetty P., Draenert R., Addo M.M., Feeney M., Tang Y., Holmes E.C., Allen T., Prado J.G., Altfeld M., Brander C., Dixon C., Ramduth D., Jeena P., Thomas S.A., St John A., Roach T.A., Kupfer B., Luzzi G., Edwards A., Taylor G., Lyall H., Tudor-Williams G., Novelli V., Martinez-Picado J., Kiepiela P., Walker B.D., Goulder P.J. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 2004;10(3):282–289.
    1. Loeb L.A., Essigmann J.M., Kazazi F., Zhang J., Rose K.D., Mullins J.I. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. U.S.A. 1999;96:1492–1497.
    1. López-Bueno A., Mateu M.G., Almendral J.M. High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host. J. Virol. 2003;77(4):2701–2708.
    1. López-Bueno A., Villarreal L.P., Almendral J.M. Parvovirus variation for disease: A difference with RNA viruses? Curr. Top. Microbiol. Immunol. 2006;299
    1. Lopez-Labrador F.X., Ampurdanes S., Gimenez-Barcons M., Guilera M., Costa J., Jimenez de Anta M.T., Sanchez-Tapias J.M., Rodes J., Saiz J.C. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon] Hepatology. 1999;29(3):897–903.
    1. Lu L., Nakano T., Orito E., Mizokami M., Robertson B.H. Evaluation of accumulation of hepatitis C virus mutations in a chronically infected chimpanzee: comparison of the core, E1, HVR1, and NS5b regions. J. Virol. 2001;75(6):3004–3009.
    1. Maag D., Castro C., Hong Z., Cameron C.E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 2001;276(49):46094–46098.
    1. Maggi F., Fornai C., Vatteroni M.L., Giorgi M., Morrica A., Pistello M., Cammarota G., Marchi S., Ciccorossi P., Bionda A., Bendinelli M. Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma. J. Gen. Virol. 1997;78(Pt 7):1521–1525.
    1. Mansky L.M., Le Rouzic E., Benichou S., Gajary L.C. Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies. J. Virol. 2003;77(3):2071–2080.
    1. Marcus P.I., Rodriguez L.L., Sekellick M.J. Interferon induction as a quasispecies marker of vesicular stomatitis virus populations. J. Virol. 1998;72(1):542–549.
    1. Margeridon S., Lachaux A., Trepo C., Zoulim F., Kay A. A quasi-monoclonal anti-HBs response can lead to immune escape of ‘wild-type’ hepatitis B virus. J. Gen. Virol. 2005;86(Pt6):1687–1693.
    1. Martell M., Esteban J.I., Quer J., Genesca J., Weiner A., Esteban R., Guardia J., Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 1992;66(5):3225–3229.
    1. Martin V., Perales C., Davila M., Domingo E. Viral fitness can influence the repertoire of virus variants selected by antibodies. J. Mol. Biol. 2006;362:44–54.
    1. Martinot-Peignoux M., Marcellin P., Pouteau M., Castelnau C., Boyer N., Poliquin M., Degott C., Descombes I., Le Breton V., Milotova V. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995;22(4 Pt 1):1050–1056.
    1. Mas A., Ulloa E., Bruguera M., Furcic I., Garriga D., Fabregas S., Andreu D., Saiz J.C., Diez J. Hepatitis C virus population analysis of a single-source nosocomial outbreak reveals an inverse correlation between viral load and quasispecies complexity. J. Gen. Virol. 2004;85(Pt 12):3619–3626.
    1. Matsumori A., Yutani C., Ikeda Y., Kawai S., Sasayama S. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab. Invest. 2000;80(7):1137–1142.
    1. Matsumori A., Shimada T., Chapman N.M., Tracy S.M., Mason J.W. Myocarditis and heart failure associated with hepatitis C virus infection. J. Card. Fail. 2006;12(4):293–298.
    1. Mayr E. Driving forces in evolution. An analysis of natural selection. In: Morse S.S., editor. The Evolutionary Biology of Viruses. Raven Press; New York: 1994.
    1. Menéndez-Arias L. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Prog. Nucl. Acid Res. Mol. Biol. 2002;71:91–147.
    1. Menéndez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 2002;23(8):381–388.
    1. Minskaia E., Hertzig T., Gorbalenya A.E., Campanacci V., Cambillau C., Canard B., Ziebuhr J. Discovery of an RNA virus 3′ → 5′ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc. Natl. Acad. Sci. U.S.A. 2006;103(13):5108–5113.
    1. Mongkolsapaya J., Dejnirattisai W., Xu X.N., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., Sawasdivorn S., Duangchinda T., Dong T., Rowland-Jones S., Yenchitsomanus P.T., McMichael A., Malasit P., Screaton G. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 2003;9(7):921–927.
    1. Mongkolsapaya J., Duangchinda T., Dejnirattisai W., Vasanawathana S., Avirutnan P., Jairungsri A., Khemnu N., Tangthawornchaikul N., Chotiyarnwong P., Sae-Jang K., Koch M., Jones Y., McMichael A., Xu X., Malasit P., Screaton G. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J. Immunol. 2006;176(6):3821–3829.
    1. Moreno I.M., Malpica J.M., Rodriguez-Cerezo E., Garcia-Arenal F. A mutation in tomato aspermy cucumovirus that abolishes cell-to-cell movement is maintained to high levels in the viral RNA population by complementation. J. Virol. 1997;71(12):9157–9162.
    1. Morishima C., Polyak S.J., Ray R., Doherty M.C., Di Bisceglie A.M., Malet P.F., Bonkovsky H.L., Sullivan D.G., Gretch D.R., Rothman A.L., Koziel M.J., Lindsay K.L. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J. Infect. Dis. 2006;193(7):931–940.
    1. Naegeli, H. (1997) Mechanisms of DNA damage recognition in mammalian cells. Landes Bioscience, Austin, Texas.
    1. Nagy P.D., Simon A.E. New insights into the mechanisms of RNA recombination. Virology. 1997;235:1–9.
    1. Naito M., Hayashi N., Hagiwara H., Hiramatsu N., Kasahara A., Fusamoto H., Kamada T. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology. 1994;19(4):871–875.
    1. Nájera I., Holguín A., Quiñones-Mateu M.E., Muñoz-Fernández M.A., Nájera R., López-Galíndez C., Domingo E. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 1995;69(1):23–31.
    1. Nakao H., Okamoto H., Fukuda M., Tsuda F., Mitsui T., Masuko K., Iizuka H., Miyakawa Y., Mayumi M. Mutation rate of GB virus C/hepatitis G virus over the entire genome and in subgenomic regions. Virology. 1997;233(1):43–50.
    1. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282(5386):103–107.
    1. Neyts J. Selective inhibitors of hepatitis C virus replication. Antiviral Res. 2006;71(2–3):363–371.
    1. Nijhuis M., Schuurman R., de Jong D., Erickson J., Gustchina E., Albert J., Schipper P., Gulnik S., Boucher C.A. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS. 1999;13(17):2349–2359.
    1. Noguchi C., Ishino H., Tsuge M., Fujimoto Y., Imamura M., Takahashi S., Chayama K. G to A hypermutation of hepatitis B virus. Hepatology. 2005;41(3):626–633.
    1. Noppornpanth S., Lien T.X., Poovorawan Y., Smits S.L., Osterhaus A.D., Haagmans B.L. Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. J. Virol. 2006;80(15):7569–7577.
    1. Nousbaum J., Polyak S.J., Ray S.C., Sullivan D.G., Larson A.M., Carithers R.L., Jr., Gretch D.R. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J. Virol. 2000;74(19):9028–9038.
    1. Novella I.S. Contributions of vesicular stomatitis virus to the understanding of RNA virus evolution. Curr. Opin. Microbiol. 2003;6(4):399–405.
    1. Novella I.S., Quer J., Domingo E., Holland J.J. Exponential fitness gains of RNA virus populations are limited by bottleneck effects. J. Virol. 1999;73(2):1668–1671.
    1. Nowak M., Schuster P. Error thresholds of replication in finite populations mutation frequencies and the onset of Muller's ratchet. J. Theor. Biol. 1989;137(4):375–395.
    1. Nowak M.A., Anderson R.M., McLean A.R., Wolfs T.F., Goudsmit J., May R.M. Antigenic diversity thresholds and the development of AIDS. Science. 1991;254(5034):963–969.
    1. Núñez J.I., Baranowski E., Molina N., Ruiz-Jarabo C.M., Sánchez C., Domingo E., Sobrino F. A single amino acid substitution in nonstructural protein 3A can mediate adaptation of foot-and-mouth disease virus to the guinea pig. J. Virol. 2001;75(8):3977–3983.
    1. Ogata N., Alter H.J., Miller R.H., Purcell R.H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 1991;88(8):3392–3396.
    1. Okada S., Akahane Y., Suzuki H., Okamoto H., Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology. 1992;16(3):619–624.
    1. Okamoto H., Kojima M., Okada S., Yoshizawa H., Iizuka H., Tanaka T., Muchmore E.E., Peterson D.A., Ito Y., Mishiro S. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology. 1992;190(2):894–899.
    1. Page K.M., Nowak M.A. Unifying evolutionary dynamics. J. Theor. Biol. 2002;219(1):93–98.
    1. Pal S., Sullivan D.G., Kim S., Lai K.K., Kae J., Cotler S.J., Carithers R.L., Jr., Wood B.L., Perkins J.D., Gretch D.R. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology. 2006;130(4):1107–1116.
    1. Pallier C., Castera L., Soulier A., Hezode C., Nordmann P., Dhumeaux D., Pawlotsky J.M. Dynamics of hepatitis B virus resistance to lamivudine. J. Virol. 2006;80(2):643–653.
    1. Pariente N., Airaksinen A., Domingo E. Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J. Virol. 2003;77(12):7131–7138.
    1. Parker W.B. Metabolism and antiviral activity of ribavirin. Virus Res. 2005;107(2):165–171.
    1. Parrish C.R., Kawaoka Y. The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses. Annu. Rev. Microbiol. 2005;59:553–586.
    1. Pawlotsky J.M. Hepatitis C virus resistance to antiviral therapy. Hepatology. 2000;32(5):889–896.
    1. Pawlotsky J.M. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res. 2003;59(1):1–11.
    1. Pawlotsky J.M. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol. 2006;299:261–284.
    1. Pfeiffer J.K., Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U.S.A. 2003;100(12):7289–7294.
    1. Pfeiffer J.K., Kirkegaard K. Increased fidelity reduces poliovirus fitness under selective pressure in mice. PLoS Pathogens. 2005;1:102–110.
    1. Polyak S.J., Faulkner G., Carithers R.L., Jr., Corey L., Gretch D.R. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. J. Infect. Dis. 1997;175(5):1101–1107.
    1. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet. 1998;352(9138):1426–1432.
    1. Puig-Basagoiti F., Saiz J.C., Forns X., Ampurdanes S., Gimenez-Barcons M., Franco S., Sanchez-Fueyo A., Costa J., Sanchez-Tapias J.M., Rodes J. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. J. Med. Virol. 2001;65(1):35–44.
    1. Qin H., Shire N.J., Keenan E.D., Rouster S.D., Eyster M.E., Goedert J.J., Koziel M.J., Sherman K.E. HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood. 2005;105(2):533–541.
    1. Quer J., Murillo P., Martell M., Gomez J., Esteban J.I., Esteban R., Guardia J. Subtype mutations in the envelope 2 region including phosphorylation homology domain of hepatitis C virus do not predict effectiveness of antiviral therapy. J. Viral Hepat. 2004;11(1):45–54.
    1. Quer J., Esteban J.I., Cos J., Sauleda S., Ocana L., Martell M., Otero T., Cubero M., Palou E., Murillo P., Esteban R., Guardia J. Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection. J. Virol. 2005;79(24):15131–15141.
    1. Quiñones-Mateu M.E., Arts E. Virus fitness: concept, qunatification, and application to HIV population dynamics. Curr. Top. Microbiol. Immunol. 2006;299:83–140.
    1. Qureshi, S.A., 2006. Hepatitis C virus-biology, host evasion strategies, and promising new therapies on the horizon. Med. Res. Rev., in press.
    1. Regoes R.R., Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science. 2006;312(5772):389–391.
    1. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 2005;5(3):215–229.
    1. Roque-Afonso A.M., Ducoulombier D., Di Liberto G., Kara R., Gigou M., Dussaix E., Samuel D., Feray C. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J. Virol. 2005;79(10):6349–6357.
    1. Rothman A.L., Morishima C., Bonkovsky H.L., Polyak S.J., Ray R., Di Bisceglie A.M., Lindsay K.L., Malet P.F., Chang M., Gretch D.R., Sullivan D.G., Bhan A.K., Wright E.C., Koziel M.J. Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology. 2005;41(3):617–625.
    1. Roux L., Simon A.E., Holland J.J. Effects of defective interfering viruses on virus replication and pathogenesis in vitro and in vivo. Adv. Virus Res. 1991;40:181–211.
    1. Rowe C.L., Baker S.C., Nathan M.J., Fleming J.O. Evolution of mouse hepatitis virus: detection and characterization of spike deletion variants during persistent infection. J. Virol. 1997;71(4):2959–2969.
    1. Ruiz-Jarabo C.M., Arias A., Baranowski E., Escarmís C., Domingo E. Memory in viral quasispecies. J. Virol. 2000;74:3543–3547.
    1. Ruiz-Jarabo C.M., Ly C., Domingo E., de la Torre J.C. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) Virology. 2003;308(1):37–47.
    1. Saakian D.B., Hu C.K. Exact solution of the Eigen model with general fitness functions and degradation rates. Proc. Natl. Acad. Sci. U.S.A. 2006;103(13):4935–4939.
    1. Saiz J.C., Lopez-Labrador F.X., Ampurdanes S., Dopazo J., Forns X., Sanchez-Tapias J.M., Rodes J. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J. Infect. Dis. 1998;177(4):839–847.
    1. Sánchez G., Bosch A., Gómez-Mariano G., Domingo E., Pinto R. Evidence for quasispecies distributions in the human hepatitis A virus genome. Virology. 2003;315:34–42.
    1. Sánchez G., Bosch A., Pinto R.M. Genome variability and capsid structural constraints of hepatitis a virus. J. Virol. 2003;77(1):452–459.
    1. Sato S., Wong S.K., Lazinski D.W. Hepatitis delta virus minimal substrates competent for editing by ADAR1 and ADAR2. J. Virol. 2001;75(18):8547–8555.
    1. Schaub M., Keller W. RNA editing by adenosine deaminases generates RNA and protein diversity. Biochimie. 2002;84(8):791–803.
    1. Serviene E., Shapka N., Cheng C.P., Panavas T., Phuangrat B., Baker J., Nagy P.D. Genome-wide screen identifies host genes affecting viral RNA recombination. Proc. Natl. Acad. Sci. U.S.A. 2005;102(30):10545–10550.
    1. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418(6898):646–650.
    1. Smith D.B., Pathirana S., Davidson F., Lawlor E., Power J., Yap P.L., Simmonds P. The origin of hepatitis C virus genotypes. J. Gen. Virol. 1997;78:321–328.
    1. Solé R.V., Sardanyes J., Diez J., Mas A. Information catastrophe in RNA viruses through replication thresholds. J. Theor. Biol. 2006;240(3):353–359.
    1. Squadrito G., Leone F., Sartori M., Nalpas B., Berthelot P., Raimondo G., Pol S., Brechot C. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology. 1997;113(2):567–572.
    1. Steinhauer D.A., Domingo E., Holland J.J. Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene. 1992;122(2):281–288.
    1. Steitz T.A. DNA polymerases: structural diversity and common mechanisms. J. Biol. Chem. 1999;274(25):17395–17398.
    1. Suspene R., Guetard D., Henry M., Sommer P., Wain-Hobson S., Vartanian J.P. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2005;102(23):8321–8326.
    1. Suspene R., Henry M., Guillot S., Wain-Hobson S., Vartanian J.P. Recovery of APOBEC3-edited human immunodeficiency virus G → A hypermutants by differential DNA denaturation PCR. J. Gen. Virol. 2005;86(Pt 1):125–129.
    1. Swetina J., Schuster P. Self-replication with errors. A model for polynucleotide replication. Biophys. Chem. 1982;16(4):329–345.
    1. Tai P.C., Banik D., Lin G.I., Pai S., Pai K., Lin M.H., Yuoh G., Che S., Hsu S.H., Chen T.C., Kuo T.T., Lee C.S., Yang C.S., Shih C. Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J. Virol. 1997;71(6):4852–4856.
    1. Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999;285(5424):107–110.
    1. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., Govindarajan S., Purcell R.H., Chisari F.V. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. U.S.A. 2002;99(24):15661–15668.
    1. Timm J., Lauer G.M., Kavanagh D.G., Sheridan I., Kim A.Y., Lucas M., Pillay T., Ouchi K., Reyor L.L., Schulze zur Wiesch J., Gandhi R.T., Chung R.T., Bhardwaj N., Klenerman P., Walker B.D., Allen T.M. CD8 epitope escape and reversion in acute HCV infection. J. Exp. Med. 2004;200(12):1593–1604.
    1. Tracy S., Chapman N.M., Drescher K.M., Kono K., Tapprich W. Evolution of virulence in picornaviruses. Curr. Top. Microbiol. Immunol. 2006;299:193–209.
    1. Valente L., Nishikura K. ADAR gene family and A-to-I RNA editing: diverse roles in posttranscriptional gene regulation. Prog. Nucleic Acid Res. Mol. Biol. 2005;79:299–338.
    1. Vignuzzi M., Stone J.K., Arnold J.J., Cameron C.E., Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature. 2006;439:344–348.
    1. Vo N.V., Young K.C., Lai M.M.C. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry. 2003;42(35):10462–10471.
    1. Wang T.C., Chao M. RNA recombination of hepatitis delta virus in natural mixed-genotype infection and transfected cultured cells. J. Virol. 2005;79(4):2221–2229.
    1. Weiner A., Erickson A.L., Kansopon J., Crawford K., Muchmore E., Hughes A.L., Houghton M., Walker C.M. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc. Natl. Acad. Sci. U.S.A. 1995;92(7):2755–2759.
    1. Wilke C.O. Quasispecies theory in the context of population genetics. BMC Evol. Biol. 2005;5:44.
    1. Wilke C.O., Ronnewinkel C., Martinetz T. Dynamic fitness landscapes in molecular evolution. Physics Reports. 2001;349:395–446.
    1. Wyatt C.A., Andrus L., Brotman B., Huang F., Lee D.H., Prince A.M. Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J. Virol. 1998;72(3):1725–1730.
    1. Yamamoto K., Horikita M., Tsuda F., Itoh K., Akahane Y., Yotsumoto S., Okamoto H., Miyakawa Y., Mayumi M. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J. Virol. 1994;68(4):2671–2676.
    1. Yang J., Xing K., Deng R., Wang J., Wang X. Identification of Hepatitis B virus putative intergenotype recombinants by using fragment typing. J. Gen. Virol. 2006;87(Pt 8):2203–2215.
    1. Yeo A.E., Ghany M., Conry-Cantilena C., Melpolder J.C., Kleiner D.E., Shih J.W., Hoofnagle J.H., Alter H.J. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J. Viral. Hepat. 2001;8(4):256–263.
    1. Young K.C., Lindsay K.L., Lee K.J., Liu W.C., He J.W., Milstein S.L., Lai M.M. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology. 2003;38(4):869–878.
    1. Yuki N., Hayashi N., Moribe T., Matsushita Y., Tabata T., Inoue T., Kanazawa Y., Ohkawa K., Kasahara A., Fusamoto H., Kamada T. Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies. Hepatology. 1997;25(2):439–444.
    1. Zhou S., Liu R., Baroudy B.M., Malcolm B.A., Reyes G.R. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology. 2003;310(2):333–342.

Source: PubMed

3
Abonneren